• Submit to IJMS Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• About
• Open Access Policy

• Abstract
• Full-Text PDF [1782 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Fejzo, MS.
• Anderson, L
• von Euw, EM.
• Kalous, O
• Avliyakulov, NK.
• Haykinson, MJ.
• Konecny, GE.
• Finn, RS.
• Slamon, DJ.
• [+] on Google Scholar
• Fejzo, MS.
• Anderson, L
• von Euw, EM.
• Kalous, O
• Avliyakulov, NK.
• Haykinson, MJ.
• Konecny, GE.
• Finn, RS.
• Slamon, DJ.
• [+] on PubMed
• Fejzo, MS.
• Anderson, L
• von Euw, EM.
• Kalous, O
• Avliyakulov, NK.
• Haykinson, MJ.
• Konecny, GE.
• Finn, RS.
• Slamon, DJ.

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Int. J. Mol. Sci. 2013, 14(2), 3094-3109; doi:10.3390/ijms14023094

Article

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

Marlena S. Fejzo ^1,* , Lee Anderson ¹ , Erika M. von Euw ¹ , Ondrej Kalous ¹ , Nuraly K. Avliyakulov ² , Michael J. Haykinson ² , Gottfried E. Konecny ¹ , Richard S. Finn ¹  and Dennis J. Slamon ¹

¹ Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA ² Department of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA

* Author to whom correspondence should be addressed.

Received: 16 January 2013; in revised form: 25 January 2013 / Accepted: 28 January 2013 / Published: 1 February 2013

(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)

Download PDF Full-Text [1782 KB, uploaded 6 February 2013 16:34 CET]

Abstract: Approximately 25,000 ovarian cancers are diagnosed in the U.S. annually, and 75% are in the advanced stage and largely incurable. There is critical need for early detection tools and novel treatments. Proteasomal ubiquitin receptor ADRM1 is a protein that is encoded by the ADRM1 gene. Recently, we showed that among 20q13-amplified genes in ovarian cancer, ADRM1 overexpression was the most highly correlated with amplification and was significantly upregulated with respect to stage, recurrence, and metastasis. Its overexpression correlated significantly with shorter time to recurrence and overall survival. Array-CGH and microarray expression of ovarian cancer cell lines provided evidence consistent with primary tumor data that ADRM1 is a 20q13 amplification target. Herein, we confirm the ADRM1 amplicon in a second ovarian cancer cohort and define a minimally amplified region of 262 KB encompassing seven genes. Additionally, using RNAi knock-down of ADRM1 in naturally amplified cell line OAW42 and overexpression of ADRM1 via transfection in ES2, we show that (1) ADRM1 overexpression increases proliferation, migration, and growth in soft agar, and (2) knock-down of ADRM1 results in apoptosis. Proteomic analysis of cells with ADRM1 knock-down reveals dysregulation of proteins including CDK-activating kinase assembly factor MAT1. Taken together, the results indicate that amplified ADRM1 is involved in cell proliferation, migration and survival in ovarian cancer cells, supporting a role as an oncogene and novel therapeutic target for ovarian cancer.

Keywords: ADRM1; oncogene; ovarian cancer

Article Statistics

Cite This Article